Page 129 - 2020_09-Haematologica-web

Somatic mutations in DLBCL
untreated diffuse large B-cell lymphoma. J
Clin Oncol. 2017:35(31):3529-3537.
4. Intlekofer AM, Joffe E, Batlevi CL, et al. Integrated DNA/RNA targeted genomic profiling of diffuse large B-cell lymphoma using a clinical assay. Blood Cancer J. 2018;
8(6):60.
5. Morin RD, Mendez-Lago M, Mungall AJ, et
al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature. 2011;476(7360):298-303.
6. Pasqualucci L, Trifonov V, Fabbri G, et al. Analysis of the coding genome of diffuse large B-cell lymphoma. Nat Genet. 2011; 43(9):830-837.
7. Zhang J, Grubor V, Love CL, et al. Genetic heterogeneity of diffuse large B-cell lym- phoma. Proc Natl Acad Sci U S A. 2013; 110(4):1398-1403.
8. Schmitz R, Wright GW, Huang DW, et al. Genetics and pathogenesis of diffuse large- B-cell lymphoma. N Engl J Med. 2018; 378(15):1396-1407.
9. Chapuy B, Stewart C, Dunford AJ, et al. Molecular subtypes of diffuse large-B-cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018;24(5):679-690.
10. Lunning MA, Green MR. Mutation of chro- matin modifiers; an emerging hallmark of germinal center B-cell lymphomas. Blood Cancer J. 2015;5:e361.
11. Jardin F, Jais JP, Molina TJ, et al. Diffuse large B-cell lymphomas with CDKN2A deletion have a distinct gene expression sig- nature and a poor prognosis under R- CHOP treatment: a GELA study. Blood. 2010;116(7):1092-1104.
12. Davis RE, Brown KD, Siebenlist U, Staudt LM. Constitutive nuclear factor kappaB
activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med. 2001;194(12):1861-1874.
13. Davis RE, Ngo VN, Lenz G, et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature. 2010; 463(7277):88-92.
14. Young RM, Shaffer AL, Phelan JD, Staudt LM. B-cell receptor signaling in diffuse large B-cell lymphoma. Semin Hematol. 2015;52(2):77-85.
15. Lenz G, Wright G, Dave SS, et al. Stromal gene signatures in large-B-cell lymphomas. N Eng J Med. 2008;359(22):2313-2323.
16. Scott DW, Wright GW, Williams PM, et al. Determining cell-of-origin subtypes of dif- fuse large B-cell lymphoma using gene expression in formalin-fixed paraffin- embedded tissue. Blood. 2014;123(8):1214- 1217.
17. Xu-Monette ZY, Wu L, Visco C, et al. Mutational profile and prognostic signifi- cance of TP53 in diffuse large B-cell lym- phoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study. Blood. 2012;120(19):3986-3996.
18. Fernandez-Rodriguez C, Bellosillo B, Garcia-Garcia M, et al. MYD88 (L265P) mutation is an independent prognostic fac- tor for outcome in patients with diffuse large B-cell lymphoma. Leukemia. 2014; 28(10):2104-2106.
19. Reddy A, Zhang J, Davis NS, et al. Genetic and functional drivers of diffuse large B cell lymphoma. Cell. 2017;171(2):481-494.e15.
20. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579- 586.
21.
22.
23.
24.
25.
26.
27.
28.
Frampton GM, Fichtenholtz A, Otto GA, et al. Development and validation of a clinical cancer genomic profiling test based on mas- sively parallel DNA sequencing. Nat Biotechnol. 2013;31(11):1023-1031.
He J, Abdel-Wahab O, Nahas MK, et al. Integrated genomic DNA/RNA profiling of hematologic malignancies in the clinical setting. Blood. 2016;127(24):3004-3014. Schuetz JM, Johnson NA, Morin RD, et al. BCL2 mutations in diffuse large B-cell lymphoma. Leukemia. 2012;26(6):1383- 1390.
Sehn LH, Oestergaard MZ, Trněný M, et al. Prognostic impact of BCL2 and MYC expression and translocation in untreated DLBCL: results from the phase III GOYA study. Hematol Oncol. 2017;35(S2):131- 133.
Souers AJ, Leverson JD, Boghaert ER, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013;19(2):202- 208.
Lohr JG, Stojanov P, Lawrence MS, et al. Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc Natl Acad Sci U S A. 2012; 109(10):3879-3884.
McCabe MT, Ott HM, Ganji G, et al. EZH2 inhibition as a therapeutic strategy for lym- phoma with EZH2-activating mutations. Nature. 2012;492(7427):108-112.
Roberts AW, Huang D. Targeting BCL2 with BH3 mimetics: basic science and clin- ical application of venetoclax in chronic lymphocytic leukemia and related B cell malignancies. Clin Pharmacol Ther. 2017; 101(1):89-98.
haematologica | 2020; 105(9)
2307